North America Continuous Glucose Monitoring Market | 2034
Wiki Article
The burden of diabetes continues to escalate in North America, demanding effective, real-time solutions for blood glucose control. As a result, continuous glucose monitoring (CGM) systems have emerged as a vital tool, revolutionizing how patients and healthcare providers manage diabetes. The North America continuous glucose monitoring market was valued at USD 6.56 Billion in 2024, driven by the increasing prevalence of diabetes and an upsurge in innovative CGM product launches. The market is expected to grow at a CAGR of 14.50% between 2025 and 2034, reaching a value of approximately USD 25.41 Billion by 2034. The integration of wearable tech, AI-driven analytics, and digital health platforms continues to redefine diabetic care, with CGM at the forefront of this transformation. Market share in the North America CGM market is currently dominated by a few leading players who offer integrated solutions combining accuracy, ease of use, and data connectivity. Among the key segments, sensors form the largest share, being replaced periodically and driving recurring revenue. Meanwhile, Type 1 diabetes patients make up a significant portion of the user base, given the necessity for precise insulin regulation. The United States holds the lion’s share of the regional market, owing to higher healthcare expenditures, favorable reimbursement policies, and widespread adoption of advanced health monitoring technologies. Canada, while smaller in scale, is witnessing growing acceptance of CGM devices driven by public health initiatives and increasing awareness. Leading companies with significant market share include: Abbott Dexcom, Inc. Medtronic PLC Senseonics, Inc. Byram Healthcare Centers, Inc. Hoffmann-La Roche Limited These companies offer differentiated products with features such as smartphone connectivity, predictive glucose alerts, and implantable sensors. The growth trajectory of the CGM market in North America is underpinned by several key drivers. One of the primary catalysts is the increasing incidence of both Type 1 and Type 2 diabetes, driven by aging populations, sedentary lifestyles, and rising obesity rates. CGM systems offer a superior alternative to traditional finger-prick glucose monitoring by providing continuous, real-time glucose readings, which significantly improves glycemic control and reduces the risk of complications. Technological innovation is another pivotal growth engine. Modern CGM systems incorporate features like AI-based predictive alerts, integration with insulin pumps, and cloud-based data sharing for telehealth applications. This digitization is enhancing patient adherence and enabling physicians to make data-informed decisions remotely. Moreover, a noticeable trend is the growing use of CGM among non-insulin-dependent Type 2 diabetes patients, as clinicians begin to recognize the preventive and therapeutic benefits of tighter glucose monitoring. Wearability, miniaturization of devices, and cost reduction are further accelerating adoption. In recent years, the North America CGM market has witnessed notable milestones and strategic movements: Dexcom, one of the industry leaders, launched the Dexcom G7, a next-gen CGM system offering smaller size, faster warm-up time, and seamless app integration. The device gained FDA approval and was quickly adopted by U.S. healthcare providers. Abbott expanded access to its FreeStyle Libre systems by partnering with insurance companies and retail pharmacies, significantly improving affordability and accessibility. In 2024, Senseonics introduced an updated version of its Eversense E3, the only long-term implantable CGM device, extending sensor wear up to 180 days, thus reducing the frequency of replacements. These examples reflect the market’s dynamic pace, characterized by competitive innovation and an increasing focus on user convenience and long-term monitoring solutions. The North America CGM market is highly competitive, with key players investing in R&D to create devices with greater accuracy, longer sensor lifespans, and improved interoperability with insulin delivery systems. The emphasis is shifting from standalone glucose monitors to ecosystem-based solutions, where CGM data is integrated with broader health platforms and electronic health records (EHRs). From a regulatory standpoint, the U.S. Food and Drug Administration (FDA) has accelerated approvals under digital health guidelines, streamlining access for patients while maintaining safety and efficacy standards. Canada, under Health Canada’s Medical Devices Bureau, is also promoting innovation through flexible policies that accommodate rapid advancements. Reimbursement policies, especially in the United States, continue to play a pivotal role in CGM adoption. Medicare and private insurers have broadened coverage for CGM devices, particularly for seniors and individuals with recurrent hypoglycemia, boosting uptake across multiple age groups. According to Expert Market Research, the increasing shift toward value-based care models is further enhancing the role of CGM in diabetes management, as it supports better clinical outcomes, reduces emergency visits, and enhances quality of life. By Components: Sensors Transmitters Receivers By Application: Type 1 Diabetes Type 2 Diabetes Others By Age Group: Adult Population Child Population By End User: Hospitals & Clinics Home Healthcare Others By Region: United States of America Canada Abbott Dexcom, Inc. Medtronic PLC Senseonics, Inc Byram Healthcare Centers, Inc. Hoffmann-La Roche Limited As the prevalence of diabetes continues to surge across North America, CGM systems are set to play an even greater role in disease management strategies. With continual advancements in sensor technology, connectivity, and user experience, these devices are evolving into essential components of modern, patient-centric diabetic care. Browse More Reports Healthcare Cloud Computing Market Assisted Reproductive Technology Market About Us: Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others. Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector. Media Contact: Company Name: Claight CorporationContinuous Glucose Monitoring Market Share
Continuous Glucose Monitoring Market Growth & Trends
Continuous Glucose Monitoring Market Case Studies & News
Continuous Glucose Monitoring Market Analysis
Market Segmentation
Key Players in the North America Continuous Glucose Monitoring Market:
Contact Person: Roshan Kumar, Digital Marketing
Email: [email protected]
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com